169 related articles for article (PubMed ID: 23423631)
1. A novel self-assembly albumin nanocarrier for reducing doxorubicin-mediated cardiotoxicity.
Yuan A; Wu J; Song C; Tang X; Qiao Q; Zhao L; Gong G; Hu Y
J Pharm Sci; 2013 May; 102(5):1626-35. PubMed ID: 23423631
[TBL] [Abstract][Full Text] [Related]
2. Liver cancer targeting of Doxorubicin with reduced distribution to the heart using hematoporphyrin-modified albumin nanoparticles in rats.
Chang JE; Shim WS; Yang SG; Kwak EY; Chong S; Kim DD; Chung SJ; Shim CK
Pharm Res; 2012 Mar; 29(3):795-805. PubMed ID: 21971829
[TBL] [Abstract][Full Text] [Related]
3. Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy.
Guo H; Lai Q; Wang W; Wu Y; Zhang C; Liu Y; Yuan Z
Int J Pharm; 2013 Jul; 451(1-2):1-11. PubMed ID: 23618965
[TBL] [Abstract][Full Text] [Related]
4. Augmented anticancer efficacy of doxorubicin-loaded polymeric nanoparticles after oral administration in a breast cancer induced animal model.
Jain AK; Swarnakar NK; Das M; Godugu C; Singh RP; Rao PR; Jain S
Mol Pharm; 2011 Aug; 8(4):1140-51. PubMed ID: 21557558
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo study of Gal-OS self-assembled nanoparticles for liver-targeting delivery of doxorubicin.
Guo H; Zhang D; Li T; Li C; Guo Y; Liu G; Hao L; Shen J; Qi L; Liu X; Luan J; Zhang Q
J Pharm Sci; 2014 Mar; 103(3):987-93. PubMed ID: 24549734
[TBL] [Abstract][Full Text] [Related]
6. Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats.
Ammar el-SM; Said SA; Suddek GM; El-Damarawy SL
Can J Physiol Pharmacol; 2011 Apr; 89(4):269-76. PubMed ID: 21526973
[TBL] [Abstract][Full Text] [Related]
7. Comparison of pharmacokinetics, tissue distribution and pharmacodynamics of liposomal and free doxorubicin in tumour-bearing mice following intratumoral injection.
Ren S; Li C; Dai Y; Li N; Wang X; Tian F; Zhou S; Qiu Z; Lu Y; Zhao D; Chen X; Chen D
J Pharm Pharmacol; 2014 Sep; 66(9):1231-9. PubMed ID: 24716458
[TBL] [Abstract][Full Text] [Related]
8. A duplex oligodeoxynucleotide-dendrimer bioconjugate as a novel delivery vehicle for doxorubicin in in vivo cancer therapy.
Lee IH; Yu MK; Kim IH; Lee JH; Park TG; Jon S
J Control Release; 2011 Oct; 155(1):88-95. PubMed ID: 20854858
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin delivery to 3D multicellular spheroids and tumors based on boronic acid-rich chitosan nanoparticles.
Wang X; Zhen X; Wang J; Zhang J; Wu W; Jiang X
Biomaterials; 2013 Jun; 34(19):4667-79. PubMed ID: 23537667
[TBL] [Abstract][Full Text] [Related]
10. Exercise mitigates cardiac doxorubicin accumulation and preserves function in the rat.
Jensen BT; Lien CY; Hydock DS; Schneider CM; Hayward R
J Cardiovasc Pharmacol; 2013 Sep; 62(3):263-9. PubMed ID: 23644988
[TBL] [Abstract][Full Text] [Related]
11. In vitro evaluation of doxorubicin-incorporated magnetic albumin nanospheres.
Zeybek A; Şanlı-Mohamed G; Ak G; Yılmaz H; Şanlıer ŞH
Chem Biol Drug Des; 2014 Jul; 84(1):108-15. PubMed ID: 24524300
[TBL] [Abstract][Full Text] [Related]
12. Albumin-Albumin/Lactosylated Core-Shell Nanoparticles: Therapy to Treat Hepatocellular Carcinoma for Controlled Delivery of Doxorubicin.
Teran-Saavedra NG; Sarabia-Sainz JA; Velázquez-Contreras EF; Ramos-Clamont Montfort G; Pedroza-Montero M; Vazquez-Moreno L
Molecules; 2020 Nov; 25(22):. PubMed ID: 33233564
[TBL] [Abstract][Full Text] [Related]
13. The tumor accumulation and therapeutic efficacy of doxorubicin carried in calcium phosphate-reinforced polymer nanoparticles.
Min KH; Lee HJ; Kim K; Kwon IC; Jeong SY; Lee SC
Biomaterials; 2012 Aug; 33(23):5788-97. PubMed ID: 22591612
[TBL] [Abstract][Full Text] [Related]
14. Oral delivery of doxorubicin using novel polyelectrolyte-stabilized liposomes (layersomes).
Jain S; Patil SR; Swarnakar NK; Agrawal AK
Mol Pharm; 2012 Sep; 9(9):2626-35. PubMed ID: 22871060
[TBL] [Abstract][Full Text] [Related]
15. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation.
Chen Y; Yang W; Chang B; Hu H; Fang X; Sha X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):406-12. PubMed ID: 23816639
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo antitumor activity of doxorubicin-loaded alginic-acid-based nanoparticles.
Cheng Y; Yu S; Wang J; Qian H; Wu W; Jiang X
Macromol Biosci; 2012 Oct; 12(10):1326-35. PubMed ID: 22887841
[TBL] [Abstract][Full Text] [Related]
17. A tumor environment responsive doxorubicin-loaded nanoparticle for targeted cancer therapy.
Zhu Q; Jia L; Gao Z; Wang C; Jiang H; Zhang J; Dong L
Mol Pharm; 2014 Oct; 11(10):3269-78. PubMed ID: 24735448
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance.
Zeng X; Morgenstern R; Nyström AM
Biomaterials; 2014 Jan; 35(4):1227-39. PubMed ID: 24210875
[TBL] [Abstract][Full Text] [Related]
19. New doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy: in-vivo characterization.
Tinkov S; Coester C; Serba S; Geis NA; Katus HA; Winter G; Bekeredjian R
J Control Release; 2010 Dec; 148(3):368-72. PubMed ID: 20868711
[TBL] [Abstract][Full Text] [Related]
20. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration.
Saad SY; Najjar TA; Alashari M
J Biochem Mol Toxicol; 2004; 18(2):78-86. PubMed ID: 15122649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]